TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17021319

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 423

Group type: COMPARATOR
Intervention: Verteporfin
Number of subjects: 423
Study: 12748510

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplementation (approximately 200 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10807815

Group type: EXPERIMENTAL
Intervention: MDI with Nebuchamber (placebo MDI through NESD, four puffs) and salbutamol 0.5 mL (2.5 mg) as NWA (group I, n = 19)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Salbutamol MDI and 0.5 mL of saline solution (group II, n = 23)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MDI with Nebuchamber (group I)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Salbutamol MDI (group II)
Number of subjects: 42

Group type: COMPARATOR
Intervention: MDI with NESD
Number of subjects: 42

Group type: COMPARATOR
Intervention: NWA
Number of subjects: 42
Study: 9298122

Group type: COMPARATOR
Intervention: Moisturizer applied before immersion (prevention study)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moisturizer applied after immersion (therapeutic study)
Number of subjects: 12
Study: 8117556

Group type: EXPERIMENTAL
Intervention: Topical treatment with mucopolysaccharide polysulphate/salicylic acid cream
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 3571545

Group type: EXPERIMENTAL
Intervention: Drionic unit
Number of subjects: 22
Study: 30607719

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) 300 J per thigh
Number of subjects: 12
Study: 28694341

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation with locking plate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative treatment with functional bracing
Number of subjects: 80
Study: 26364533

Group type: EXPERIMENTAL
Intervention: Foot reflexology massage (once a day for three days)
Number of subjects: 70
Study: 23658147

Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Attention Control Condition (ACC)
Number of subjects: 42
Study: 21677618

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 7
Study: 19808491

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA) with/without antiarrhythmic drug (AAD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antiarrhythmic drug (AAD) alone
Number of subjects: 100
Study: 17909123

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: First-episode schizophrenia group
Number of subjects: 104
Study: 15801502

Group type: EXPERIMENTAL
Intervention: Common speed treadmill run at 10.5 km x h(‐1) (absolute intensity)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Relative exercise intensity trial at 65% of VO2max
Number of subjects: 20
Study: 11194244

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 29

Group type: COMPARATOR
Intervention: Buffered regular human insulin
Number of subjects: 29
Study: 9891194

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) alone (70 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chloral hydrate/hydroxyzine (CH/H) (70 mg/kg CH + 2 mg/kg hydroxyzine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Chloral hydrate alone)
Number of subjects: 40
Study: 8015507

Group type: EXPERIMENTAL
Intervention: 2 mg/24 h administration of oestradiol valerate
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 1.5 mg/day of percutaneous 17 beta-oestradiol
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.05 mg/day of transdermic oestradiol
Number of subjects: 63
Study: 2660632

Group type: EXPERIMENTAL
Intervention: Ketotifen syrup
Number of subjects: 284

Group type: COMPARATOR
Intervention: Clemastine syrup
Number of subjects: 284
Study: 19938055

Group type: EXPERIMENTAL
Intervention: iPod 3G, iPod Photo, and iPod Touch with telemetry communication
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: iPod 3G, iPod Photo, and iPod Touch without telemetry communication
Number of subjects: 54
Study: 354474

Group type: EXPERIMENTAL
Intervention: 265 mg theophylline (150 mg slow-release)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 265 mg theophylline + 7.5 mg hydroxyzine hydrochloride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31830776

Group type: EXPERIMENTAL
Intervention: Triple therapy plus probiotics (group B)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Triple therapy plus sulforaphane (group C)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Triple therapy only (group A)
Number of subjects: 183
Study: 31306386

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study: 28443690

Group type: EXPERIMENTAL
Intervention: 7 days of vaginal micronised progesterone tablets (Group A)
Number of subjects: 303

Group type: COMPARATOR
Intervention: 5 days of vaginal micronised progesterone (Group B)
Number of subjects: 303
Study: 25818061

Group type: EXPERIMENTAL
Intervention: Bupropion, sustained-release 150 mg, twice daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 23963057

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 0.5-1.8 mg/kg per day
Number of subjects: 398

Group type: COMPARATOR
Intervention: Other early standard therapy (OEST, mainly methylphenidate)
Number of subjects: 398
Study: 20946437

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg bi-hourly for 3 nights)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (indistinguishable gum bi-hourly for 3 nights)
Number of subjects: 25
Study: 19438817

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1% with benzoyl peroxide 5% (CDP/BPO)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Adapalene 0.1% (ADA)
Number of subjects: 69
Study: 17920770

Group type: EXPERIMENTAL
Intervention: First-line treatments including certain antidepressants (tricyclic antidepressants and dual reuptake inhibitors of both serotonin and norepinephrine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel alpha2-delta ligands (gabapentin and pregabalin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid analgesics and tramadol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certain antiepileptic and antidepressant medications, mexiletine, N-methyl-D-aspartate receptor antagonists, and topical capsaicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medications
Number of subjects: 0
Study: 14717628

Group type: EXPERIMENTAL
Intervention: Angry opponent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Happy opponent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry communications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large concessions by opponent
Number of subjects: 0
Study: 12397467

Group type: EXPERIMENTAL
Intervention: (123)I-BZA(2) scintigraphy
Number of subjects: 25
Study: 9661537

Group type: EXPERIMENTAL
Intervention: Nurse-administered subcutaneous morphine
Number of subjects: 80

Group type: COMPARATOR
Intervention: i.v. patient-controlled analgesia morphine
Number of subjects: 80
Study: 2679231

Group type: EXPERIMENTAL
Intervention: 5 to 10 degrees head-up tilt
Number of subjects: 100

Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (head-up and horizontal)
Number of subjects: 100
Study: 1146857

Group type: EXPERIMENTAL
Intervention: Directive play therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nondirective play therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study: 30739922

Group type: EXPERIMENTAL
Intervention: Community Based Health Insurance (CBHI) scheme enrollment
Number of subjects: 416
Study: 28342891

Group type: EXPERIMENTAL
Intervention: Group Acceptance and Commitment Therapy (GACT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Recommended Pharmacological Treatment (RPT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: GACT vs RPT
Number of subjects: 156
Study: 25702072

Group type: EXPERIMENTAL
Intervention: Mobile phone assessment
Number of subjects: 469

Group type: COMPARATOR
Intervention: Paper assessment
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Mobile assessment
Number of subjects: 469
Study: 22893323

Group type: EXPERIMENTAL
Intervention: α‐KG and 5‐HMF supplementation (AO1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Broad based antioxidant supplementation (AO2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo group (PL)
Number of subjects: 18
Study: 21511380

Group type: EXPERIMENTAL
Intervention: Gow‐Gates mandibular nerve block
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no Gow‐Gates block)
Number of subjects: 20
Study: 18202588

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 71
Study: 17203122

Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 90

Group type: COMPARATOR
Intervention: atracurium (priming with 0.05 mg/kg followed by 0.55 mg/kg after induction of anaesthesia)
Number of subjects: 90
Study: 14679270

Group type: EXPERIMENTAL
Intervention: Efalizumab, 1 mg/kg, 12 weekly doses
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 556
Study: 11307041

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg oral dose
Number of subjects: 12
Study: 9722127

Group type: EXPERIMENTAL
Intervention: oral ornidazole 2 x 500 mg/day for 5 days
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: vaginal ornidazole 500 mg/day for 5 days
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose and vaginal ornidazole 500 mg/day for 5 days
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: oral secnidazole 2 g in a single dose and vaginal metronidazole 2 x 500 mg/day for 7 days
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: oral ornidazole 2 x 500 mg/day for 5 days and vaginal metronidazole 2 x 500 mg/day for 7 days
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: vaginal metronidazole 2 x 500 mg/day for 7 days
Number of subjects: 152
Study: 7978130

Group type: COMPARATOR
Intervention: Sufentanil 2 micrograms.ml‐1 in 0.9% sodium chloride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms.ml‐1 + adrenaline 2.5 micrograms.ml‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms.ml‐1 + clonidine 3 micrograms.ml‐1
Number of subjects: 60
Study: 2531992

Group type: COMPARATOR
Intervention: IA (Intraarterial FUdR, 0.2 mg/kg/d x 14 days/month)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IA/IV (Intraarterial FUdR + systemic 5‐FU 700 mg/m2/d x 3 days/month)
Number of subjects: 52
Study: 1187279

Group type: EXPERIMENTAL
Intervention: SGaw (specific airway conductance)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MMEF (maximum mid expiratory flow)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CV (closing volume)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FEV1 (forced expiratory volume in one second)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FVC (forced vital capacity)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MMEF (measured by spirometry)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SGaw (measured by body plethysmography)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Flow-volume parameters (measured by wedge spirometer)
Number of subjects: 24
Study: 31834936

Group type: EXPERIMENTAL
Intervention: Smartphone application providing information and support for medication abortion (MA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (high-quality comprehensive and empathic counseling on pregnancy options)
Number of subjects: 0
Study: 31018852

Group type: EXPERIMENTAL
Intervention: Referral to quitline via warm handoff
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Referral to quitline via fax
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Receipt of smoking cessation medications while hospitalized
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Discharge with a prescription
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Receipt of medication as an inpatient
Number of subjects: 1054
Study: 30059262

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 419

Group type: COMPARATOR
Intervention: Platinum-pemetrexed
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 419
Study: 27221962

Group type: COMPARATOR
Intervention: Group I (control)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Group III
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Native thiol
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Thiol values of 310.7 or below
Number of subjects: 161
Study: 24465387

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic interpersonal therapy (PIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced medical care (control)
Number of subjects: 0
Study: 22436453

Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 μg/day) supplementation for 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 20625317

Group type: COMPARATOR
Intervention: Amlodipine besilate
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 110
Study: 17981247

Group type: EXPERIMENTAL
Intervention: Stent placement (S group = 98 patients)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Non-stent placement (nS group = 103 patients)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Non-stent placement (nS group)
Number of subjects: 201
Study: 15726878

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg) + Triamterene (150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamterene (150 mg)
Number of subjects: 0
Study: 12049800

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) low dosage (100 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) medium dosage (200 mg daily)
Number of subjects: 30
Study: 10090547

Group type: COMPARATOR
Intervention: High-dose inhaled budesonide (1600 microg d(-1) for 3 d and 800 microg for 7 d)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral betamethasone (6, 4 and 2 mg for 3 d)
Number of subjects: 40
Study: 7788149

Group type: EXPERIMENTAL
Intervention: Prednisone (10 mg/day for first 12 weeks, tapering to 7.5 mg/day for weeks 13-14, 5 mg/day for weeks 15-16, and 2.5 mg/day for weeks 17-18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prednisone (after tapering)
Number of subjects: 40
Study: 2169368

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 0
Study: 376140

Group type: EXPERIMENTAL
Intervention: Therapeutic results from Mycosis Fungoides Cooperative Group protocols
Number of subjects: 376
Study: 31608832

Group type: EXPERIMENTAL
Intervention: IFM strengthening exercises for ten weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 20
Study: 28024931

Group type: EXPERIMENTAL
Intervention: High-Flux Hemodialysis (HD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 100
Study: 25968407

Group type: EXPERIMENTAL
Intervention: Pravastatin 80 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pravastatin (both doses)
Number of subjects: 30
Study: 24280904

Group type: EXPERIMENTAL
Intervention: Home-based deep breathing exercises with a positive expiratory pressure device (10-15 cm H2O), 30 slow deep breaths, 5 times a day for 2 months
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group performing no breathing exercises after discharge (n = 154)
Number of subjects: 159
Study: 22530773

Group type: EXPERIMENTAL
Intervention: CO2-insufflated ESD with duodenal balloon occlusion (duodenal balloon group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Regular CO2-insufflated ESD (regular group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 19138366

Group type: EXPERIMENTAL
Intervention: Combination of testosterone and vardenafil
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 13
Study: 17519644

Group type: EXPERIMENTAL
Intervention: Quetiapine+lithium/divalproex
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo+lithium/divalproex
Number of subjects: 200
Study: 15009968

Group type: EXPERIMENTAL
Intervention: Inspiring nitric oxide (NO) at 20±1 mg/L for 30 minutes before admission and urokinase (150x10^4 U) intravenously injected with 0.9% sodium chloride within 30 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Urokinase treatment as in test group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inspiring nitric oxide (NO) before urokinase
Number of subjects: 60
Study: 11583938

Group type: EXPERIMENTAL
Intervention: Cyclosporine withdrawal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study: 9845708

Group type: EXPERIMENTAL
Intervention: Oral itraconazole (200 mg daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 9877146

Group type: EXPERIMENTAL
Intervention: Cycling at 80% VO2max until exhaustion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cycling at 55% VO2max for 3 hours or to fatigue
Number of subjects: 18
Study: 1675705

Group type: EXPERIMENTAL
Intervention: Levamisole, 2.5 mg/kg on alternate days (31 patients)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (30 patients)
Number of subjects: 61
Study: 6822042

Group type: EXPERIMENTAL
Intervention: B15000 (Iopamidol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urografin 370
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urografin 370 plus Lignocaine
Number of subjects: 0
Study: 31075274

Group type: EXPERIMENTAL
Intervention: Single Aβ42 oligomers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger Aβ42 aggregates
Number of subjects: 0
Study: 30219038

Group type: EXPERIMENTAL
Intervention: Pictorial cigarette pack warnings
Number of subjects: 24
Study: 26796394

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 453

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support (LVAD)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: End-stage heart failure patients (N=41)
Number of subjects: 453
Study: 24828363

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (cooling to a target body temperature of 34-35°C, started within six hours of symptom onset and maintained for 24 hours)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 1500
Study: 22456865

Group type: EXPERIMENTAL
Intervention: HbA(1c) trajectory in individuals who developed diabetes
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: HbA(1c) in individuals who developed diabetes 10 years after baseline
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: HbA(1c) increase from 3 years to 1 year prediagnosis
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: Overall HbA(1c) and FPG increase in the entire group
Number of subjects: 1722
Study: 20197618

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholi acid combined with reduced glutathione
Number of subjects: 84

Group type: COMPARATOR
Intervention: Yinzhihuang intravenously combined with reduced glutathione
Number of subjects: 84
Study: 18422579

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Choreito (7.5 g/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 102
Study: 16226266

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) consumption (50ml per day for 3 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study: 12696391

Group type: EXPERIMENTAL
Intervention: Intervention 1: Sporadic, brief (30 seconds‐1 minute) and unstructured medical advice to quit.
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Intervention 2: Brief (5‐8 minutes) structured medical counselling for tobacco quitting, followed by reinforcement advice on 3 occasions during 3 months, accompanied by nicotine patches individualized according to nicotine dependence.
Number of subjects: 217
Study: 10656203

Group type: EXPERIMENTAL
Intervention: Conventional polymeric enteral diet (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soy-rich and lactose-free polymeric diet (Group B)
Number of subjects: 40
Study: 9068017

Group type: EXPERIMENTAL
Intervention: 39 mmol/L bicarbonate-buffered CAPD solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: 34 mmol/L bicarbonate-buffered CAPD solution
Number of subjects: 9
Study: 8446394

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg b.i.d. for 7 days (n = 134)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Cefaclor 13.5 mg/kg t.i.d. for 7 days (n = 136)
Number of subjects: 270
Study: 3510320

Group type: EXPERIMENTAL
Intervention: Cefotaxime (2 intravenous doses preoperatively)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 29240208

Group type: EXPERIMENTAL
Intervention: Titanium (Ti) post
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Zirconia (Zi) post
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glass-fiber (Gf) post
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: No post (NP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control tooth (vital)
Number of subjects: 31